53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 25.328515111695136
- age_years
- 49
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.616
- IL6_JAK_STAT3_SIGNALING+0.600
- INTERFERON_GAMMA_RESPONSE+0.598
- INTERFERON_ALPHA_RESPONSE+0.582
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.580
- INFLAMMATORY_RESPONSE+0.575
- COMPLEMENT+0.538
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.537
- TNFA_SIGNALING_VIA_NFKB+0.511
- OXIDATIVE_PHOSPHORYLATION+0.500
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.311
- MITOTIC_SPINDLE-0.308
- KRAS_SIGNALING_DN-0.263
- SPERMATOGENESIS-0.215
- MYC_TARGETS_V2-0.205
- HEDGEHOG_SIGNALING-0.186
- G2M_CHECKPOINT-0.121
- APICAL_SURFACE-0.023
- APICAL_JUNCTION+0.024
- MYOGENESIS+0.036
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.969 |
| 2 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.948 |
| 3 | 70203945-80F8-4FA7-8C99-FEBAD3374103 | — | — | 0.940 |
| 4 | 15FB165D-6751-4894-A904-C77EA723CFCB | — | — | 0.940 |
| 5 | 647EE729-B34A-41F0-85AB-207F8C24420B | — | — | 0.940 |
| 6 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.934 |
| 7 | 5B9DEC62-3DC7-4DE2-8B20-3E191594FCB4 | — | — | 0.934 |
| 8 | 62BFF895-C5CC-4F59-8348-2026B659FDF5 | — | — | 0.928 |
| 9 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.925 |
| 10 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.925 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.616 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.598 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.582 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.580 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.575 | Idelalisib | — uncovered |
| COMPLEMENT | 0.538 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.537 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.511 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.478 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.477 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.472 | Idelalisib | — uncovered |
| APOPTOSIS | 0.468 | Idelalisib | — uncovered |
| COAGULATION | 0.447 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.438 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.434 | Inavolisib | — uncovered |
| HYPOXIA | 0.409 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.393 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.362 | Idelalisib | — uncovered |